Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PD-1

PD-1

Brief Information

Name:Programmed cell death protein 1
Target Synonym:Programmed cell death protein 1,CD279,hPD-1,PDCD1,Programmed Cell Death 1,Systemic Lupus Erythematosus Susceptibility 2,Protein PD-1,PD1,Programmed Cell Death 1 Protein,CD279 Antigen,HPD-L,HSLE1,SLEB2,PD-1,Programmed Cell Death 1 Receptor
Number of Launched Drugs:11
Number of Drugs in Clinical Trials:110
Lastest Research Phase:Approved

Licensing

Project item Indications Research phase Cooperation demands
BBS21008 Solid tumors such as lung cancer, gastric carcinoma, esophagus cancer, cervical cancer. Pre-clinical, CMC developing; Project transfer or co-development. (the project’s company is in the startup stage and seek external cooperation to accelate drug research and development.)

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
PD1-H5256 Human Human PD-1 / PDCD1 Protein, Fc,His Tag
PD1-H5256-structure
PD1-H5256-sds
PD1-H5256-elisa_1
PD1-H52H2 Human Human PD-1 Protein, His tag (Nanoparticle)
PD1-H52H2-sds
PD1-H52H2-elisa_1
PD1-C52H9 Canine Canine PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-C52H9-structure
PD1-C52H9-sds
PD1-H82A4 Human Biotinylated Human PD-1 / PDCD1 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
PD1-H82A4-structure
PD1-H82A4-sds
PD1-H82A4-elisa_1
PD1-R52H3 Rhesus macaque Rhesus macaque PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-R52H3-structure
PD1-R52H3-sds
PD1-R52H3-elisa_1
PD1-H52H6 Human Human PD-1 / PDCD1 Full Length Protein, His Tag
PD1-H52H6-structure
PD1-H52H6-sds
PD1-H52H6-elisa_1
PD1-H82F4 Human Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™,His Tag (MALS verified)
PD1-H82F4-structure
PD1-H82F4-sds
PD1-H82F4-hplc
PD1-H82F4-elisa_1
PD1-C82E6 Cynomolgus Biotinylated Cynomolgus PD-1 / PDCD1 Protein, His,Avitag™
PD1-C82E6-structure
PD1-C82E6-sds
PD1-C82E6-elisa_1
PD1-HP2F2 Human PE-Labeled Human PD-1 / PDCD1 Protein, Fc,His Tag (recommended for neutralizing assay)
PD1-HP2F2-structure
PD1-H5255 Human Human PD-1 / PDCD1 Protein, Mouse IgG2a Fc Tag (HPLC-verified)
PD1-H5255-structure
PD1-H5255-sds
PD1-H5255-hplc
PD1-H5255-elisa_1
PD1-H522a Human Human PD-1 / PDCD1 Protein, His Tag, low endotoxin (MALS verified)
PD1-H522a-structure
PD1-H522a-sds
PD1-H522a-hplc
PD1-H522a-elisa_1
EPC-V1 Monkey ELISA Assay Kit for Anti-PD-1 h-mAb in Monkey Serum
EPC-V1-elisa_1
EPM-V1 Mouse ELISA Assay Kit for Anti-PD-1 h-mAb in Mouse Serum
EPM-V1-elisa_1
PD1-H5259 Human Human PD-1 / PDCD1 Protein, Llama IgG2b Fc Tag, low endotoxin
PD1-H5259-structure
PD1-H5259-sds
PD1-H5259-elisa_1
EPH-V1 Human ELISA Assay Kit for Anti-PD-1 h-mAb in Human Serum
EPH-V1-elisa_1
PD1-H82F1 Human Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™ (MALS verified)
PD1-H82F1-structure
PD1-H82F1-sds
PD1-H82F1-elisa_1
PD1-RB5251 Rabbit Rabbit PD-1 / PDCD1 Protein, Fc Tag
PD1-RB5251-structure
PD1-RB5251-sds
PD1-RB5251-elisa_1
PD1-M52A4 Mouse Mouse PD-1 / PDCD1 Protein, Mouse IgG2a Fc Tag
PD1-M52A4-structure
PD1-M52A4-sds
PD1-M52A4-elisa_1
PD1-R52H2 Rat Rat PD-1 / PDCD1 Protein, His Tag
PD1-R52H2-structure
PD1-R52H2-sds
PD1-R52H2-elisa_1
PD1-H82E4 Human Biotinylated Human PD-1 / PDCD1 Protein, Avitag™,His Tag (recommended for biopanning) (MALS verified)
PD1-H82E4-structure
PD1-H82E4-sds
PD1-H82E4-elisa_1
PD1-R52H0 Rabbit Rabbit PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-R52H0-structure
PD1-R52H0-sds
PD1-M82F4 Mouse Biotinylated Mouse PD-1 / PDCD1 Protein, Fc,Avitag™ (MALS Verified)
PD1-M82F4-structure
PD1-M82F4-sds
PD1-M82F4-elisa_1
PD1-R5253 Rat Rat PD-1 / PDCD1 Protein, Fc Tag
PD1-R5253-structure
PD1-R5253-sds
PD1-R5253-elisa_1
PD1-M5259 Mouse Mouse PD-1 / PDCD1 Protein, Fc Tag
PD1-M5259-structure
PD1-M5259-sds
PD1-M5259-elisa_1
PD1-M5259-elisa_2
PD1-H5284 Human Human PD-1 / PDCD1 Protein, Strep Tag
PD1-H5284-structure
PD1-H5284-sds
PD1-H5284-elisa_1
PD1-M5228 Mouse Mouse PD-1 / PDCD1 Protein, His Tag
PD1-M5228-structure
PD1-M5228-sds
PD1-C5254 Cynomolgus Cynomolgus PD-1 / PDCD1 Protein, Fc Tag (MALS verified)
PD1-C5254-structure
PD1-C5254-sds
PD1-C5254-elisa_1
PD1-C5223 Cynomolgus Cynomolgus PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-C5223-structure
PD1-C5223-sds
PD1-C5223-elisa_1
PD1-C5223-elisa_2
PD1-H5257 Human Human PD-1 / PDCD1 Protein, Fc Tag, low endotoxin (MALS Verified)
PD1-H5257-structure
PD1-H5257-sds
PD1-H5257-hplc
PD1-H5257-elisa_1
PD1-H5257-elisa_2
PD1-H5221 Human Human PD-1 / PDCD1 Protein, His Tag (MALS Verified)
PD1-H5221-structure
PD1-H5221-sds
PD1-H5221-hplc
PD1-H5221-elisa_1
PD1-H5221-elisa_2

Part of Bioactivity data

PD1-HP2F2-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that PE-Labeled Human PD-1, Fc,His Tag (Cat. No. PD1-HP2F2) can bind to 293T cells overexpressing human PD-L1. 1 μL stock solution per million cells (QC tested).

PD1-HP2F2-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of PE-Labeled Human PD-1, Fc,His Tag (Cat. No. PD1-HP2F2) to 293T overexpressing PD-L1 was inhibited by increasing concentration of neutralizing anti-human PD-L1 antibody. The IC50 is 0.29 μg/mL (QC tested).

PD1-M5259-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) on Protein A Chip can bind Mouse PD-L1, His Tag (Cat. No. PD1-M5220) with an affinity constant of 2.16 μM as determined in SPR assay (Biacore T200) (Routinely tested).

PD1-M5259-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Mouse PD-L1, His Tag (Cat. No. PD1-M5220) on CM5 Chip via Anti-His antibody can bind Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) with an affinity constant of 1.37 μM as determined in SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

PDCD1,PD1,CD279,SLEB2

Background

How a therapeutic antibody is metabolized in the body is pertinently relevant to its efficacy. Therefore, pharmacokinetics study is an important part of the drug development. PD-1 is probably the most targeted molecule in today’s pharmaceutical industry, thanking to the clinical success of Keytruda® and Opdivo®. Many investigational anti-PD-1 mAbs are being developed. There is a growing need for a standard assay that can be used to facilitate the study of their pharmacokinetics.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Prolgolimab BCD-100 Approved Biocad Forteca Russian Federation Melanoma Biocad 2020-04-01 Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms Details
Dostarlimab WBP-285; TSR-042; ANB-011 Approved Anaptysbio JEMPERLI United States Solid tumours Glaxosmithkline Llc 2021-04-21 Solid tumours; Ovarian Neoplasms; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Zimberelimab AB-122; GLS-010; WBP-3055 Approved Harbin Gloria Pharmaceuticals Co Ltd, Wuxi Apptec Co Ltd Mainland China Hodgkin Disease Guangzhou Yuheng Biotechnology Co Ltd 2021-08-25 Multiple Myeloma; Adenocarcinoma; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Urinary Bladder Neoplasms; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Hodgkin Disease; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Stomach Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Ovarian Neoplasms Details
Penpulimab AK-105 Approved Zhongshan Akeso Biopharma Co Ltd 安尼可 Mainland China Hodgkin Disease Zhengda Tianqing Kangfang (Shanghai) Biomedical Technology Co Ltd 2021-08-03 Solid tumours; Neoplasms; Hodgkin Disease; Nasopharyngeal Carcinoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Camrelizumab SHR-1210; INCSHR-1210; HR-301210 Approved Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd AiRuiKa, 艾瑞卡, 艾立妥 Mainland China Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Suzhou Suncadia Biopharmaceuticals Co Ltd 2019-05-29 Sarcoma; Melanoma; Uterine Cervical Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Genital Neoplasms, Female; Urologic Neoplasms; Lymphoma, Extranodal NK-T-Cell; Respiratory Tract Neoplasms; Solid tumours; Nasopharyngeal Carcinoma; Breast Neoplasms; Lung Diseases; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Hodgkin Disease; Triple Negative Breast Neoplasms; Bronchial Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Ovarian Neoplasms; Carcinoma, Bronchogenic Details
Toripalimab SO-001; TAB-001; JS-001; JS-001sc Approved Suzhou Union Biopharm Biosciences Co Ltd, Shanghai Junshi Biosciences Co Ltd 拓益 Mainland China Carcinoma, Transitional Cell Shanghai Junshi Biological Engineering Co Ltd 2018-12-17 Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Lymphoma; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Liposarcoma; Neuroendocrine Tumors; Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Kidney Neoplasms Details
Nivolumab ONO-4538; ono-0123; BMS-936558; MDX-1106; BMS-936558-01 Approved Bristol-Myers Squibb Company, Ono Pharmaceutical Co Ltd 欧狄沃, Opdivo EU Esophageal Neoplasms Bristol-Myers Squibb Pharma Eeig 2014-07-04 Diarrhea; Lung Neoplasms; Ureteral Neoplasms; Genital Neoplasms, Female; Peritoneal Neoplasms; Hepatitis C; Colorectal Neoplasms; Neuroblastoma; Brain Neoplasms; Hepatitis B; Esophageal Squamous Cell Carcinoma; Lymphoma, Mantle-Cell; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Sarcoma, Ewing; Microsatellite Instability; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Esophageal adenocarcinoma; Large intestine neoplasm; Thyroid Cancer, Papillary; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Multiple Myeloma; Urogenital Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Glioma; Endometrial Neoplasms; Lymphoma; Carcinoma, Squamous Cell; Chondrosarcoma; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Hepatitis B, Chronic; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Medulloblastoma; Skin Melanoma; Ependymoma; Irritable Bowel Syndrome; Hematologic Ne Details
Tislelizumab BGB-A317; VDT-482 Approved Beigene Ltd 百泽安 Mainland China Carcinoma, Hepatocellular Beigene (Shanghai) Biotechnology Co Ltd 2019-12-26 Lymphoma, Mantle-Cell; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Lymphoma; Lymphoma, T-Cell; Carcinoma, Squamous Cell; Esophageal adenocarcinoma; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Breast Neoplasms; Lymphoma, Follicular; Lymphoma, Extranodal NK-T-Cell; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Hodgkin Disease; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell, Marginal Zone Details
Sintilimab IBI-308 Approved Innovent Biologics(Suzhou) Co Ltd Tyvyt, 达伯舒 Mainland China Carcinoma, Hepatocellular Innovent Biologics(Suzhou) Co Ltd 2018-12-24 Osteosarcoma; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Small Cell; Endometrial Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Lymphoma, Extranodal NK-T-Cell; Nasopharyngeal Carcinoma; Adenocarcinoma of Lung; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Hodgkin Disease; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours Details
Pembrolizumab SCH-900475; h409A11; MK-3475 Approved Merck & Co Inc 可瑞达, Keytruda Japan Endometrial Neoplasms Msd Kk 2014-09-04 Solid tumours; Head and Neck Neoplasms; Endocrine Gland Neoplasms; Kidney Neoplasms; Ovarian Neoplasms; Lymphoma, B-Cell; Liver Neoplasms; Skin Melanoma; Leiomyosarcoma; Biliary Tract Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Thoracic Neoplasms; Stomach Neoplasms; Carcinoma; Carcinoma, Merkel Cell; Anus Neoplasms; Bronchial Neoplasms; Carcinoid Tumor; Viremia; Rectal Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms, Glandular and Epithelial; Glioblastoma; Skin Neoplasms; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Neoplasms, Squamous Cell; Lymphoma, Large B-Cell, Diffuse; Salivary Gland Neoplasms; Nasopharyngeal Neoplasms; Adenocarcinoma of Lung; Inflammatory Breast Neoplasms; Neuroectodermal Tumors; Ganglioglioma; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Microsatellite instability-high cancer; Neuroendocrine Tumors; Digestive System Neop Details
Cemiplimab REGN-2810; SAR-439684 Approved Regeneron Pharmaceuticals Inc Libtayo United States Carcinoma, Non-Small-Cell Lung Regeneron Pharmaceuticals Inc 2018-09-28 Diffuse Intrinsic Pontine Glioma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Peritoneal Neoplasms; Ovarian Neoplasms; Hepatitis B; Prostatic Neoplasms; Central Nervous System Neoplasms; Glioblastoma; Skin Neoplasms; Hodgkin Disease; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Solid tumours Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) LXF-821 Phase 1 Clinical University Of Pennsylvania, Novartis Pharma Ag Glioblastoma Details
Programmed cell death 1 antibody (Sun Yat-sen University) Phase 2 Clinical Sun Yat-Sen University Carcinoma, Hepatocellular Details
9MW1111 9MW1111; 9MW-1111; 9-MW1111; 9-MW-1111 Phase 1 Clinical Mabwell (Shanghai) Bioscience Co Ltd Solid tumours Details
EBV-Specific TCR-T Cell therapy (Xinqiao Hospital of Chongqing) Phase 2 Clinical Xinqiao Hospital, Army Medical University Squamous Cell Carcinoma of Head and Neck Details
ONO-4685 ONO-4685 Phase 1 Clinical Merus Autoimmune Diseases; Lymphoma, T-Cell Details
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T Phase 2 Clinical Shanghai Cell Therapy Research Institute Solid tumours Details
TY-101 TY-101; TY101 Phase 2 Clinical Tayu Huaxia Biotech Medical Group Co Ltd Solid tumours; Lymphoma Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) Phase 2 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Solid tumours; Sarcoma Details
Izuralimab XmAb-104; XmAb-23104 Phase 1 Clinical Xencor Nasopharyngeal Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Breast Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms Details
RO-7121661 RG-7769; RO-7121661 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
ONCR-177 ONCR-177 Phase 1 Clinical Oncorus Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma Details
SSGJ-705 SSGJ-705 Phase 1 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Solid tumours Details
RG-6279 RG-6279 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours Details
JS-201 JS-201 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Neoplasms Details
PD-1 knockout engineered T cells (Chengdu MedGenCell) Phase 2 Clinical West China Hospital Of Sichuan University, Chengdu Medgencell Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
LBL-015 LBL-015 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Solid tumours Details
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) Phase 2 Clinical Shanghai Cell Therapy Research Institute Neoplasms Details
RB-0004 RB-0004 Phase 1 Clinical Reyoung Pharmaceutical Co Ltd Solid tumours; Lymphoma Details
EBV-specific TCR-T cell with anti-PD1 auto-secreted element Phase 2 Clinical Tcrcure Biopharma Ltd Squamous Cell Carcinoma of Head and Neck Details
MK-3475A MK-3475A Merck Sharp & Dohme Corp Details
Vudalimab XmAb-20717; XmAb-717 Phase 2 Clinical Xencor Nasopharyngeal Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Thymoma; Endometrial Neoplasms; Colorectal Neoplasms; Astrocytoma; Vulvar Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Prostatic Neoplasms; Adnexal Diseases; Mesothelioma; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours Details
CC-90006 C-90006; CC-90006 Phase 1 Clinical Anaptysbio Autoimmune Diseases; Psoriasis Details
PD-1 knockout engineered T cells (Cell Biotech) Phase 1 Clinical Cell Biotech Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Prostatic Neoplasms Details
Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) Phase 1 Clinical Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd Solid tumours; Stomach Neoplasms Details
W0180 Phase 1 Clinical Pierre Fabre Medicament Solid tumours Details
SI-B003 SI-B003 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
PE0105 PE-0105 Phase 1 Clinical Shanghai Yunyi Health Technology Development Co Ltd Neoplasms Details
BAT-1308 BAT-1308 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours Details
PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) Phase 2 Clinical Anhui Korton Biological Technology Co Ltd, Hangzhou Cancer Hospital Esophageal Neoplasms Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Multiple Myeloma Details
BCD-217 BCD-217 Phase 2 Clinical Biocad Melanoma Details
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell Details
89Zr-N-sucDf-pembrolizumab Phase 1 Clinical Merck & Co Inc, Umcg The University Medical Center Groningen Carcinoma, Non-Small-Cell Lung; Melanoma Details
CD-200-AR-L CD-200-AR-L; hP-1-A-8 Phase 1 Clinical University Of Minnesota Glioblastoma Details
Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) Phase 2 Clinical Anhui Anke Biotechnology (Group) Co Ltd Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lung Neoplasms Details
LZM-009 LZM-009 Phase 2 Clinical Livzon(Group) Pharmaceutical Factory Solid tumours; Thymoma; Carcinoma, Non-Small-Cell Lung Details
QL1604 QL1604; QL-1604 Phase 3 Clinical Qilu Pharmaceutical Co Ltd Solid tumours; Uterine Cervical Neoplasms; Adenocarcinoma Details
SL-279252 TAK-252; SL-279252 Phase 1 Clinical Takeda Pharmaceutical Co Ltd, Shattuck Labs Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
MEDI-0680 AMP-514; MEDI-0680 Phase 2 Clinical Medimmune Kidney Neoplasms; Lymphoma, B-Cell; Carcinoma, Renal Cell Details
MiHA-loaded PD-L silenced DC vaccination (Radboud University) Phase 2 Clinical Radboud University Nijmegen Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
Sym-021 Sym-021 Phase 1 Clinical Symphogen Solid tumours; Lymphoma; Neoplasm Metastasis Details
YBL-006 YBL-006; YBL 006 Phase 1 Clinical Solid tumours Details
BA1104 LY-01015; BA-1104 Phase 1 Clinical Luye Pharma Group Ltd Liver Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Urinary Bladder Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Recombinant human anti-PD-1 monoclonal antibody(Hec Biological) Phase 1 Clinical Dongguan City Hec Biological Medicine Res And Development Co Ltd Stomach Neoplasms; Esophageal adenocarcinoma Details
T3011疱疹病毒(深圳市亦诺微医药) MVR-T3011 Phase 2 Clinical Immvira Co Ltd Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Mesothelioma; Breast Neoplasms; Lymphoma; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
EMB-02 EMB-02 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours Details
PD-1 knockout EBV-CTL (Nanjing Medical University) Phase 2 Clinical Nanjing Medical University Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma Details
Recombinant human PD-1 antibody herpes simplex virus Phase 1 Clinical Yangsheng Tang Co Ltd, Xiamen University Liver Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Melanoma; Uterine Cervical Neoplasms Details
IMU-201 IMU-201 Phase 1 Clinical Imugene Adenocarcinoma of Lung; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
HerinCAR-PD1 Phase 2 Clinical Ningbo Cancer Hospital Solid tumours Details
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) Phase 1 Clinical Second Affiliated Hospital Of Zhejiang University School Of Medicine Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma Details
Recombinant human anti-PD-1 monoclonal antibody(Cspc Pharmaceutical Technology ,Shijiazhuang) Phase 1 Clinical Cspc Pharmaceutical Technology (Shijiazhuang) Co Ltd Bile Duct Neoplasms Details
STW204 STW-204; AI025; AI-025 Phase 1 Clinical Suzhou Stainwei Biotech Inc Solid tumours; Neoplasms Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) Phase 1 Clinical Shanxi Weiqidaguangming Pharmaceutical Co Ltd Solid tumours Details
HPV E6-specific TCR-T cells SIM-325; TC-E202 Phase 1 Clinical Tcrcure Biopharma Ltd Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms Details
INSIX RA (Indus Biotech) Clinical Indus Biotech Pvt Ltd Arthritis, Rheumatoid; Inflammation Details
CMAB-819 CMAB8-19 Phase 1 Clinical Sinomab Bioscience Ltd Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Cetrelimab JNJ-3283; JNJ-63723283 Phase 3 Clinical Johnson & Johnson Neoplasms; Carcinoma, Transitional Cell; Multiple Myeloma; Urinary Bladder Neoplasms Details
GNR-051 GNR-051 Phase 1 Clinical Generium Pharmaceuticals Carcinoma, Renal Cell; Melanoma; Carcinoma, Non-Small-Cell Lung Details
MW-11 MW-11 Phase 1 Clinical Mabwell (Shanghai) Bioscience Co Ltd Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Nasopharyngeal Neoplasms; Hodgkin Disease; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma Details
MEDI-5752 MEDI-5752 Phase 1 Clinical Medimmune Llc Solid tumours; Carcinoma, Renal Cell; Neoplasms Details
AZD-7789 AZD-7789 Phase 2 Clinical AstraZeneca Ag Carcinoma, Non-Small-Cell Lung Details
IBI-318(Innovent Biologics/Eli Lilly And Company) LY-3434172; LY3434172; IBI-318 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
Treprilimab Clinical Sun Yat-Sen University Oropharyngeal Neoplasms Details
Recombinant humanized anti-PD-1 monoclonal antibody (Bio-Thera) BAT-1306 Phase 2 Clinical Bio-Thera Solutions Ltd Solid tumours; Stomach Neoplasms Details
Rituximab/Paclitaxel AR-160 Phase 1 Clinical Mayo Clinic Lymphoma, Non-Hodgkin Details
Pimivalimab JTX-4014 Phase 2 Clinical Jounce Therapeutics Neoplasms; Carcinoma, Non-Small-Cell Lung Details
AZD-2936 AZD-2936 Phase 2 Clinical Astrazeneca Plc Carcinoma, Non-Small-Cell Lung Details
HX-009 HX-009 Phase 2 Clinical Hangzhou Hansi Biomedicine Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd Liver Neoplasms; Hematologic Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Lymphoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
SSI-361 LVGN-3616; SSI-361 Phase 2 Clinical Lyvgen Biopharma(HK)Ltd Neoplasms Details
SSGJ-706 SSGJ-706 Phase 1 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Solid tumours; Lymphoma Details
QL-1706 QL-1706; PSB-205 Phase 2 Clinical Qilu Pharmaceutical Co Ltd Solid tumours; Liver Neoplasms; Neoplasms; Uterine Cervical Neoplasms Details
Tebotelimab MGD-013; PD-1 X LAG-3 Phase 3 Clinical Macrogenics Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Endometrial Neoplasms; Cholangiocarcinoma; Solid tumours; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms Details
ZG-005 ZG-005 Phase 2 Clinical Suzhou Zelgen Biopharmaceuticals Co Ltd Solid tumours Details
609-A 609-A Phase 2 Clinical Shenyang Sunshine Pharmaceutical Co Ltd Solid tumours; Sarcoma Details
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) ICTCAR-014 Phase 2 Clinical Innovative Cellular Therapeutics Co Ltd Lymphoma, Non-Hodgkin Details
PH-762 PH-762 Phase 1 Clinical Breast Neoplasms; Melanoma Details
Rulonilimab F-520 Phase 2 Clinical Shandong New Time Pharmaceutical Co Ltd Solid tumours; Lymphoma, T-Cell, Peripheral; Carcinoma, Transitional Cell; Lymphoma, Large B-Cell, Diffuse; Neurolymphomatosis; Lymphoma; Uterine Cervical Neoplasms Details
NIR-178 PBF-509; NIR-178 Phase 2 Clinical Palobiofarma Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoma; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Lorigerlimab MGD-019 Phase 1 Clinical Macrogenics Skin Melanoma; Solid tumours; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Recombinant human anti-PD-1 monoclonal antibody(Sumgen) SG-001; SYSA1802 Phase 2 Clinical Hangzhou Sumgen Biotechnology Co Ltd Solid tumours; Biliary Tract Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Mesothelioma; Cholangiocarcinoma; Peritoneal Neoplasms; Lymphoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Nofazinlimab CS-1003 Phase 3 Clinical Cstone Pharmaceuticals Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular Details
ABBV-1882 ABBV-1882 Phase 1 Clinical Abbvie Inc HIV Infections Details
IBI-321 IBI-321 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
IBI-319 IBI-319 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Neoplasms Details
Finotonlimab SCT-I10A Phase 3 Clinical SinoCelltech Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Fidasimtamab IBI-315 Phase 1 Clinical Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
MAX-10181 MAX-10181; MAX-1 Phase 1 Clinical Guangzhou Maxinovel Pharmaceiticals Co Ltd Solid tumours Details
Zeluvalimab AMG-404 Phase 2 Clinical Amgen Inc Solid tumours; Small Cell Lung Carcinoma; Prostatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Nivolumab/Relatlimab BMS-936558/BMS-986016; BMS-986213 Phase 3 Clinical Bristol-Myers Squibb Company Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Melanoma Details
Rosnilimab ANB-030 Phase 2 Clinical Anaptysbio Inc Alopecia Areata Details
Budigalimab ABBV-181 Phase 2 Clinical Abbvie Inc HIV Infections; Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
CA-170 AUPM-170; CA-170 Phase 1 Clinical Aurigene Solid tumours Details
AMG-256 AMG-256 Phase 1 Clinical Amgen Inc Solid tumours Details
Pembrolizumab/Quavonlimab MK-1308A Phase 3 Clinical Merck Sharp & Dohme Corp, Msd Ireland (Carlow), Moshadong R & D (China) Co Ltd Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma Details
Spartalizumab(Novartis Pharma) PDR-001 Phase 3 Clinical Novartis Pharma Ag Lymphoma; Neuroendocrine Tumors; Nasopharyngeal Carcinoma; Breast Neoplasms; Prostatic Neoplasms; Sarcoma; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Bone Marrow Diseases; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Chordoma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Leukemia, Myeloid, Acute; Sarcoma, Alveolar Soft Part; Carcinoma, Squamous Cell; Esophageal adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma; Carcinoma, Hepatocellular; Persistent Fetal Circulation Syndrome; Stomach Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Leukemia, Myeloid; Liver Neoplasms; Leukemia; Hematologic Diseases; Kidney Neoplasms; Preleukemia; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Thyroid Carcinoma, Anaplastic; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Neoplasm Details
Ivonescimab AK-112 Phase 3 Clinical Zhongshan Akeso Biopharma Co Ltd Ovarian Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Triple Negative Breast Neoplasms; Genital Neoplasms, Female; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis Details
Mavezelimab/Pembrolizumab MK-4280A Phase 3 Clinical Msd Ireland (Carlow) Merck Sharp & Dohme Corp, Moshadong R & D (China) Co Ltd Solid tumours; Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Peramprizumab Phase 2 Clinical Sun Yat-Sen University Nasopharyngeal Carcinoma Details
LY-3462817 LY-3462817 Phase 2 Clinical Eli Lilly And Company Arthritis, Rheumatoid; Psoriasis Details
RO-7247669 RO-7247669 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Liver Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Retifanlimab INCMGA-0012; INCMGA-00012; MGA-012 Phase 3 Clinical Macrogenics Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Head and Neck Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Carcinoma, Merkel Cell; Anus Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Solid tumours Details
Sasanlimab PF-06801591; PF-6801591; RN-888 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Carcinoma, Transitional Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Bile Duct Neoplasms; Prostatic Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Solid tumours; Pancreatic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms Details
PF-07209960 PF-07209960 Phase 1 Clinical Pfizer Inc Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Pembrolizumab/Vibostolimab MK-7684A Phase 3 Clinical Hematologic Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Lung Neoplasms; Gallbladder Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
SHR-1901 SHR-1901 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd Neoplasms Details
Pembrolizumab biosimilar (biocad) BCD-201 Phase 1 Clinical Biocad Solid tumours Details
Ezabenlimab BI-754091 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Head and Neck Neoplasms; Solid tumours; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message